BR112015022820A8 - ensaio para selecionar um regime de tratamento para um indivíduo com depressão, uso de um composto compreendendo folato, composição e kit - Google Patents

ensaio para selecionar um regime de tratamento para um indivíduo com depressão, uso de um composto compreendendo folato, composição e kit Download PDF

Info

Publication number
BR112015022820A8
BR112015022820A8 BR112015022820A BR112015022820A BR112015022820A8 BR 112015022820 A8 BR112015022820 A8 BR 112015022820A8 BR 112015022820 A BR112015022820 A BR 112015022820A BR 112015022820 A BR112015022820 A BR 112015022820A BR 112015022820 A8 BR112015022820 A8 BR 112015022820A8
Authority
BR
Brazil
Prior art keywords
depression
individual
folate
compound
treatment regimen
Prior art date
Application number
BR112015022820A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015022820A2 (pt
Inventor
Kronlage David
Papakostas George
O Koch Harold Jr
Fava Maurizio
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/796,362 external-priority patent/US9546401B2/en
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112015022820A2 publication Critical patent/BR112015022820A2/pt
Publication of BR112015022820A8 publication Critical patent/BR112015022820A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112015022820A 2013-03-12 2014-03-11 ensaio para selecionar um regime de tratamento para um indivíduo com depressão, uso de um composto compreendendo folato, composição e kit BR112015022820A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361777650P 2013-03-12 2013-03-12
US13/796,362 US9546401B2 (en) 2011-11-14 2013-03-12 Assays and methods for selecting a treatment regimen for a subject with depression
US201361914338P 2013-12-10 2013-12-10
PCT/US2014/023695 WO2014164882A1 (en) 2013-03-12 2014-03-11 Assays and methods for selecting a treatment regimen for a subject with depression

Publications (2)

Publication Number Publication Date
BR112015022820A2 BR112015022820A2 (pt) 2017-07-18
BR112015022820A8 true BR112015022820A8 (pt) 2019-11-26

Family

ID=51658998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022820A BR112015022820A8 (pt) 2013-03-12 2014-03-11 ensaio para selecionar um regime de tratamento para um indivíduo com depressão, uso de um composto compreendendo folato, composição e kit

Country Status (12)

Country Link
EP (1) EP2973135A4 (es)
JP (1) JP2016518816A (es)
KR (1) KR20150131147A (es)
CN (1) CN105518685A (es)
AU (1) AU2014248949A1 (es)
BR (1) BR112015022820A8 (es)
CA (1) CA2904418A1 (es)
IL (1) IL241156A0 (es)
MX (1) MX2015012520A (es)
RU (1) RU2015143177A (es)
TW (1) TW201437635A (es)
WO (1) WO2014164882A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013270422A1 (en) * 2012-06-01 2015-01-22 Brc Operations Pty Limited Biomakers for treatment outcomes
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
EP3229812A4 (en) 2014-12-08 2018-10-03 Glycom A/S Synthetic composition for treating metabolic disorders
WO2016135707A1 (en) * 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
US10780103B2 (en) 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
EP3368046B1 (en) 2015-10-28 2022-07-27 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
KR101911339B1 (ko) * 2017-07-17 2018-10-25 고려대학교 산학협력단 카테콜아민-o-메틸 전이 효소 유전자의 메틸화 비율을 이용한 우울증 진단에 관한 정보를 제공하는 방법
CN112423887B (zh) * 2018-07-12 2024-06-07 韩国生命工学研究院 核酸扩增用基板及其制造方法
CN109234383A (zh) * 2018-11-07 2019-01-18 上海康黎医学检验所有限公司 与抗精神疾病药相关的试剂盒、目标基因及其制备、snp标记、snp识别和应用
CN109966498A (zh) * 2019-03-25 2019-07-05 北京坤秋健康科技有限公司 一种抗抑郁症的药物组合物及其用途
CN111500709A (zh) * 2020-05-12 2020-08-07 珠海横琴润孚创新科技有限公司 一种代谢性疾病基因检测与临床深度数据分析方法
KR102570458B1 (ko) * 2021-01-21 2023-08-24 전남대학교산학협력단 여성의 우울증 위험도 예측용 바이오마커, 상기 바이오마커를 이용한 여성의 우울증 위험도 진단에 대한 정보제공방법 및 진단키트
JP7432190B2 (ja) 2021-03-01 2024-02-16 勝彦 山▲崎▼ 抗うつ薬抵抗性の大うつ病患者を識別するための、データの取得方法およびキット
CN116103385A (zh) * 2021-11-11 2023-05-12 中国科学院深圳理工大学(筹) 一种预测抑郁障碍患者对治疗反应的基因诊断试剂盒和系统
WO2023237306A1 (en) 2022-06-09 2023-12-14 Dsm Ip Assets B.V. Nutritional composition comprising gos and hmos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216737A1 (en) * 2005-03-10 2006-09-28 John Bodeau Methods for multiplex amplification
EP2435586A4 (en) * 2009-05-29 2012-12-26 Genomind Llc METHODS OF EVALUATION AND TREATMENT OF DEPRESSION VIA USE OF ANALYSIS OF SIMPLE NUCLEOTIDE POLYMORPHISMS
US20120115147A1 (en) * 2010-11-05 2012-05-10 Lombard Jay L Neuropsychiatric test reports
CN102781259A (zh) * 2009-09-30 2012-11-14 加利福尼亚大学董事会 辅因子及个体使用方法
US20140088035A1 (en) * 2010-12-03 2014-03-27 The General Hospital Corporation Treating schizophrenia
RU2622082C2 (ru) * 2011-11-14 2017-06-09 Нестек С.А. Анализы и способы выбора режима лечения пациента с депрессией

Also Published As

Publication number Publication date
MX2015012520A (es) 2016-01-12
CA2904418A1 (en) 2014-10-09
WO2014164882A1 (en) 2014-10-09
RU2015143177A (ru) 2017-04-18
KR20150131147A (ko) 2015-11-24
AU2014248949A1 (en) 2015-09-10
TW201437635A (zh) 2014-10-01
EP2973135A1 (en) 2016-01-20
JP2016518816A (ja) 2016-06-30
BR112015022820A2 (pt) 2017-07-18
EP2973135A4 (en) 2016-11-16
IL241156A0 (en) 2015-11-30
CN105518685A (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
BR112015022820A8 (pt) ensaio para selecionar um regime de tratamento para um indivíduo com depressão, uso de um composto compreendendo folato, composição e kit
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
BR112014015955A8 (pt) uso terapêutico subcutâneo de inibidor de dpp-4
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
BR112018006039A2 (pt) terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
AR101740A1 (es) Terapia de combinación y composiciones

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements